Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
Our objective was to compare lipid profiles of schizophrenic patients treated with conventional antipsychotics or risperidone to those of patients switched to olanzapine. Our results indicate that in patients switched to olanzapine, fasting serum lipids initially increased then returned to pretreatment levels, and endpoint lipid levels were not significantly different from those in patients remaining on conventional antipsychotics or risperidone.
Kinon
Bruce J
BJ
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA. bj_kinon@lilly.com
Liu-Seifert
Hong
H
Ahl
Jonna
J
Ahmed
Saeeduddin
S
Baker
Robert W
RW
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008137:Longitudinal Studies; D000077152:Olanzapine; D011446:Prospective Studies; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use*; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy*
D014150:Antipsychotic Agents; D008055:Lipids; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine